Drugs / Δ-9-tetrahydrocannabinol
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT05092191 | Nov 2022 → Apr 2025 overdue | multiple sclerosis | University of Montreal Hospital Centre (CHUM) | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Δ-9-tetrahydrocannabinol | “It is therefore important to carry out studies to better understand the efficacy Δ-9-tetrahydrocannabinol (THC), and cannabidiol (CBD) on MS symptoms .” NCT05092191 ↗ |
| Known as | THC | “For many years, persons with MS (PwMS) have used cannabis to relax, to reduce pain and spasticity, or to improve sleep and daily functioning, despite the lack of scientific...” PMID 39114536 ↗ Jul 2024 |
| Route | Oral | “THC and CBD will be taken as oil softgels in two divided doses per day.” NCT05092191 ↗ |